US2021340622A1PendingUtilityA1

Polynucleotides for amplification and detection of sars-cov-2

61
Assignee: TALIS BIOMEDICAL CORPPriority: Mar 23, 2020Filed: May 20, 2021Published: Nov 4, 2021
Est. expiryMar 23, 2040(~13.7 yrs left)· nominal 20-yr term from priority
Y02A50/30C12Q 2521/107C12Q 2531/119C12Q 1/701C12Q 1/6813C12Q 1/6876C12Q 2600/112C12Q 1/70C12Q 2521/101C12Q 1/6853C12Q 1/6844
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein are primers and probes related to the detection of SARS-CoV-2 via nucleic acid amplification testing (NAAT), for example to amplify and determine the presence of SARS-CoV-2 in test samples and/or to diagnose Covid-19. Specifically, the present disclosure describes primers and probes that bind to the N gene, ORF1ab, or E gene of SARS-CoV-2 coronavirus for detection via loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.

Claims

exact text as granted — not AI-modified
1 .- 30 . (canceled) 
     
     
         31 . A composition comprising SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, and SEQ ID NO: 54. 
     
     
         32 . The composition of  claim 31 , further comprising a molecular beacon comprising a fluorophore, a quencher and a polynucleotide. 
     
     
         33 . The composition of  claim 32 , wherein the polynucleotide comprises a sequence selected from the group consisting of: nucleotides 5-22 of SEQ ID NO: 75, nucleotides 5-22 of SEQ ID NO: 76, nucleotides 5-22 of SEQ ID NO: 80, nucleotides 5-22 of SEQ ID NO: 81, nucleotides 4-22 of SEQ ID NO: 82, nucleotides 6-28 of SEQ ID NO: 83, nucleotides 6-25 of SEQ ID NO: 84, and nucleotides 3-23 of SEQ ID NO: 85. 
     
     
         34 . The composition of  claim 33 , wherein the polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85. 
     
     
         35 . The composition of  claim 34 , wherein the polynucleotide consists a sequence selected from the group consisting of: SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85. 
     
     
         36 . The composition of  claim 32 , wherein the fluorophore is FAM and the quencher is BHQ1. 
     
     
         37 . The composition of  claim 32 , wherein the fluorophore is ATTO 565 or Alexa 594 and the quencher is BHQ1 or BHQ2. 
     
     
         38 . The composition of  claim 31 , further comprising an intercalating dye. 
     
     
         39 . The composition of  claim 31 , further comprising a strand displacement DNA polymerase and a reverse transcriptase. 
     
     
         40 . A composition comprising a set of polynucleotides selected from the group consisting of: Set-5 and Set-9. 
     
     
         41 . A method of detecting SARS-CoV-2 in a test sample, the method comprising:
 (a) extracting nucleic acid from the test sample;   (b) amplifying a target sequence by reacting the nucleic acid extracted in step (a) with a reaction mixture comprising a strand displacement DNA polymerase activity, a reverse transcriptase activity, and a sequence-specific primer set, wherein said sequence-specific primer set is selected from the group consisting of: Set-5 and Set-9; and   (c) detecting the presence or absence of an amplification product from step (b);   wherein the presence of said amplification product is indicative of the presence of SARS-CoV-2 in the test sample.   
     
     
         42 . The method of  claim 41 , wherein the amplification in step (b) of the target sequence is performed between about 60° C. and about 67° C. for less than 30 minutes. 
     
     
         43 . The method of  claim 42 , wherein the amplification step is performed for less than fifteen minutes. 
     
     
         44 . The method of  claim 43 , wherein the amplification step is performed for less than twelve minutes. 
     
     
         45 . The method of  claim 44 , wherein the amplification step is performed for less than nine minutes. 
     
     
         46 . The method of  claim 41 , wherein detecting the presence or absence of the amplification product comprises hybridizing the amplification product with a probe comprising a polynucleotide attached to a label. 
     
     
         47 . The method of  claim 46 , wherein the label is a fluorophore. 
     
     
         48 . The method of  claim 47 , wherein the fluorophore is covalently attached to a terminus of the polynucleotide. 
     
     
         49 . The method of  claim 46 , wherein the labeled polynucleotide comprises a sequence selected from the group consisting: of nucleotides 5-22 of SEQ ID NO: 75, nucleotides 5-22 of SEQ ID NO: 76, nucleotides 5-22 of SEQ ID NO: 80, nucleotides 5-22 of SEQ ID NO: 81, nucleotides 4-22 of SEQ ID NO: 82, nucleotides 6-28 of SEQ ID NO: 83, nucleotides 6-25 of SEQ ID NO: 84, and nucleotides 3-23 of SEQ ID NO: 85. 
     
     
         50 . The method of  claim 49 , wherein the labeled polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85. 
     
     
         51 . The method of  claim 50 , wherein the sequence-specific primer set is Set-9 and the sequence of the labeled polynucleotide is SEQ ID NO: 83. 
     
     
         52 . A kit comprising the composition of  claim 31 . 
     
     
         53 . The kit of  claim 52 , further comprising a strand displacement polymerase and a reverse transcriptase. 
     
     
         54 . The kit of  claim 53 , further comprising a molecular beacon comprising a fluorophore, a quencher, and a polynucleotide. 
     
     
         55 . The kit of  claim 54 , wherein the polynucleotide comprises a sequence selected from the group consisting of: nucleotides 5-22 of SEQ ID NO: 75, nucleotides 5-22 of SEQ ID NO: 76, nucleotides 5-22 of SEQ ID NO: 80, nucleotides 5-22 of SEQ ID NO: 81, nucleotides 4-22 of SEQ ID NO: 82, nucleotides 6-28 of SEQ ID NO: 83, nucleotides 6-25 of SEQ ID NO: 84, and nucleotides 3-23 of SEQ ID NO: 85. 
     
     
         56 . The kit of  claim 55 , wherein the polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85. 
     
     
         57 . The kit of  claim 56 , wherein the polynucleotide consists a sequence selected from the group consisting of: SEQ ID NO: 75, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, and SEQ ID NO: 85. 
     
     
         58 . The kit of  claim 57 , wherein the polynucleotide consists of SEQ ID NO: 83.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.